Methods
|
Antibiotics tested
|
F
|
G
|
K
|
L
|
M
|
N
|
O
|
P
|
---|
CDS
|
Penicillin G
|
Mean annular radius (range)
|
13.2 (12–15)
|
5.5 (3–7)
|
00
|
00
|
00
|
00
|
00
|
6 (5–7)
|
Expected result
|
>9 (S)
|
3–9 (I)
|
<3 (R)
|
<3 (R)
|
<3 (R)
|
<3 (R)
|
<3 (R)
|
3–9 (I)
|
β-lactamase production
|
No
|
No
|
No
|
No
|
Yes
|
Yes
|
Yes
|
No
|
Expected result
|
No
|
No
|
No
|
No
|
Yes
|
Yes
|
Yes
|
No
|
Ciprofloxacin
|
Mean annular radius (range)
|
15 (14–17)
|
7.7 (7–9)
|
00
|
00
|
3.2 (02–4)
|
00
|
13.5 (12–15)
|
14.2 (13–16)
|
Expected result
|
≥11 (S)
|
6–10 (I)
|
<6 (R)
|
<6 (R)
|
<6 (R)
|
<6 (R)
|
≥11 (S)
|
≥11 (S)
|
Spectinomycin
|
Mean annular radius (range)
|
11 (10–11)
|
10.2 (9–11)
|
16 (15–18)
|
9.5 (8–11)
|
11 (9–13)
|
13.5 (10–17)
|
00
|
13 (11–15)
|
Expected result
|
≥6 (S)
|
≥6 (S)
|
≥6 (S)
|
≥6 (S)
|
≥6 (S)
|
≥6 (S)
|
<6 (R)
|
≥6 (S)
|
Azithromycin
|
Mean annular radius (range)
|
12.5 (10–15)
|
14 (12–16)
|
13.5 (12–15)
|
11 (9–13)
|
12 (9–15)
|
11.5 (10–13)
|
13 (12–15)
|
1.5 (0–4)
|
Expected result
|
≥8 (S)
|
≥8 (S)
|
≥8 (S)
|
≥8 (S)
|
≥8 (S)
|
≥8 (S)
|
≥8 (S)
|
<8 (R)
|
Ceftriaxone
|
Mean annular radius (range)
|
14.2 (12–16)
|
14.7 (14–16)
|
6.7 (6–8)
|
5.5 (5–7)
|
13 (12–15)
|
13.2 (12–15)
|
13.2 (13–15)
|
13.7 (13–15)
|
Expected result
|
≥10 (S)
|
≥10 (S)
|
5–9 (DS)
|
5–9 (DS)
|
≥10 (S)
|
≥10 (S)
|
≥10 (S)
|
≥10 (S)
|
MIC by Etest
|
Ceftriaxonea
|
Etest MIC ranges
|
<0.002
|
0.004–0.008
|
0.064–0.125
|
0.125–0.25
|
0.008–0.016
|
0.002–0.004
|
0.016–0.032
|
0.004–0.008
|
Expected result
|
<0.002 (S)
|
0.004–0.016 (S)
|
0.032–0.125 (DS)
|
0.064–0.25 (DS)
|
0.008–0.032 (S)
|
0.002–0.008 (S)
|
0.016–0.064 (S)
|
0.002–0.008 (S)
|
-
aMICs for control strains was performed only for ceftriaxone. DS Decreased susceptibility, S Sensitive, I intermediate, R resistant